ethyl (2E)-2-(2-morpholin-4-ylcyclopent-2-en-1-ylidene)acetate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: ethyl (2E)-2-(2-morpholin-4-ylcyclopent-2-en-1-ylidene)acetate
• 化学式: C₁₃H₁₉NO₃
• 分子量: 237.29
• InChiKey: VVQFLWDFZUIVDL-ZHACJKMWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF<br/>[FR] PROCÉDÉS DE PRÉPARATION D'ACIDE (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMÉTHYL)BENZYLOXY)-1,2,3,4-TÉTRAHYDROCYCLOPENTA]INDOL-3-YL) ACÉTIQUE ET DE SES SELS
  申请人：ARENA PHARM INC

  公开号：WO2011094008A1

  公开（公告）日：2011-08-04

  The present invention relates to processes and intermediates useful in the preparation of of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of Formula (Ia) and salts thereof, an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).

  本发明涉及用于制备（R）-2-(7-(4-环戊基-3-(三氟甲基)苄氧基)-1,2,3,4-四氢环戊[b]吲哚-3-基)乙酸及其盐的过程和中间体，该化合物是S1P1受体调节剂，用于治疗S1P1受体相关疾病，例如由淋巴细胞介导的疾病和疾病，移植排斥反应，自身免疫疾病和疾病，炎症性疾病和疾病（例如，急性和慢性炎症症状），癌症，以及具有血管完整性基础缺陷或与血管生成相关的疾病和疾病，如可能是病理性的（例如，在炎症、肿瘤发展和动脉粥样硬化中可能发生的情况）。
• PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF
  申请人：Montalban Antonio Garrido

  公开号：US20120295947A1

  公开（公告）日：2012-11-22

  The present invention relates to processes and intermediates useful in the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of Formula (Ia) and salts thereof, an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).

  本发明涉及用于制备(R)-2-(7-(4-环戊基-3-(三氟甲基)苯基氧基)-1,2,3,4-四氢环戊[b]吲哚-3-基)乙酸及其盐的过程和中间体，它是一种S1P1受体调节剂，可用于治疗S1P1受体相关疾病，例如淋巴细胞介导的疾病和疾病，移植排斥反应，自身免疫性疾病和疾病，炎症性疾病和疾病（例如急性和慢性炎症状况），癌症以及以血管完整性缺陷为基础或与血管生成相关的病症，如可能是病理性的（例如可能发生在炎症，肿瘤发展和动脉粥样硬化中）。
• Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof
  申请人：Arena Pharmaceuticals, Inc.

  公开号：US11149292B2

  公开（公告）日：2021-10-19

  The present invention relates to processes and intermediates useful in the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of Formula (Ia) and salts thereof, an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).

  本发明涉及用于制备式(Ia)的(R)-2-(7-(4-环戊基-3-(三氟甲基)苄氧基)-1,2,3,4-四氢环戊并[b]吲哚-3-基)乙酸及其盐的工艺和中间体、一种 S1P1 受体调节剂，可用于治疗与 S1P1 受体相关的疾病，例如由淋巴细胞介导的疾病和紊乱、移植排斥、自身免疫性疾病和紊乱、炎症性疾病和紊乱（如.g.,例如，急性和慢性炎症）、癌症，以及以血管完整性的潜在缺陷为特征的疾病或与血管生成有关的疾病，如病理上的血管生成（如可能发生在炎症、肿瘤发生和动脉粥样硬化中的血管生成）。
• COMPOUNDS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
  申请人：Arena Pharmaceuticals, Inc.

  公开号：EP3847158A1

  公开（公告）日：2021-07-14
• US8853419B2
  申请人：——

  公开号：US8853419B2

  公开（公告）日：2014-10-07